Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
1. MBRX expanding recruitment for pivotal Phase 2B/3 trial of Annamycin. 2. 13 subjects already enrolled; target is 20 by end of September. 3. Trial aims to recruit 45 patients for initial data unblinding in Q4 2025. 4. Unique access to early data insights boosts investor confidence. 5. Annamycin holds FDA Fast Track and Orphan Drug Designation.